JP2009511452A5 - - Google Patents

Download PDF

Info

Publication number
JP2009511452A5
JP2009511452A5 JP2008534032A JP2008534032A JP2009511452A5 JP 2009511452 A5 JP2009511452 A5 JP 2009511452A5 JP 2008534032 A JP2008534032 A JP 2008534032A JP 2008534032 A JP2008534032 A JP 2008534032A JP 2009511452 A5 JP2009511452 A5 JP 2009511452A5
Authority
JP
Japan
Prior art keywords
combination
immunostimulants
pharmaceutical composition
immunostimulant
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008534032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511452A (ja
Filing date
Publication date
Priority claimed from ES200601563A external-priority patent/ES2334472B1/es
Application filed filed Critical
Priority claimed from PCT/ES2006/000554 external-priority patent/WO2007042583A1/es
Publication of JP2009511452A publication Critical patent/JP2009511452A/ja
Publication of JP2009511452A5 publication Critical patent/JP2009511452A5/ja
Pending legal-status Critical Current

Links

JP2008534032A 2005-10-07 2006-10-05 C型肝炎の予防および治療のための免疫刺激物質の組合せ Pending JP2009511452A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200502446 2005-10-07
ES200601563A ES2334472B1 (es) 2006-06-09 2006-06-09 Combinacion inmunoestimuladora para profilaxis y tratamiento de hepatitis c.
PCT/ES2006/000554 WO2007042583A1 (es) 2005-10-07 2006-10-05 Combinación inmunoe s t imuladora para profilaxis y tratamiento de hepatitis c

Publications (2)

Publication Number Publication Date
JP2009511452A JP2009511452A (ja) 2009-03-19
JP2009511452A5 true JP2009511452A5 (https=) 2009-11-26

Family

ID=37942331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008534032A Pending JP2009511452A (ja) 2005-10-07 2006-10-05 C型肝炎の予防および治療のための免疫刺激物質の組合せ

Country Status (19)

Country Link
US (2) US20100047231A1 (https=)
EP (1) EP1949913B1 (https=)
JP (1) JP2009511452A (https=)
CN (1) CN101330928B (https=)
AT (1) ATE469657T1 (https=)
AU (1) AU2006301171B9 (https=)
BR (1) BRPI0616978A2 (https=)
CA (1) CA2625506C (https=)
CY (1) CY1110744T1 (https=)
DE (1) DE602006014720D1 (https=)
DK (1) DK1949913T3 (https=)
ES (1) ES2346570T3 (https=)
HR (1) HRP20100473T1 (https=)
PL (1) PL1949913T3 (https=)
PT (1) PT1949913E (https=)
RS (1) RS51402B (https=)
RU (1) RU2431499C2 (https=)
SI (1) SI1949913T1 (https=)
WO (1) WO2007042583A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2066339T3 (pl) 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
WO2009059018A1 (en) * 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT3097926T (pt) 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
AU2009323996A1 (en) 2008-12-03 2011-07-07 Institut Pasteur Use of phenol-soluble modulins for vaccine development
CN102770457A (zh) * 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
MX350306B (es) 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
AR094791A1 (es) 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
JP4593783B2 (ja) * 1998-07-21 2010-12-08 ゲンマブ・アクティーゼルスカブ 抗c型肝炎ウイルス抗体およびその使用
JP5175417B2 (ja) * 2000-08-17 2013-04-03 トリペップ アクチ ボラゲット リバビリンを含むワクチンおよびその使用方法
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
EP2258712A3 (en) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
EP2572714A1 (en) * 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations

Similar Documents

Publication Publication Date Title
CN101479375B (zh) Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其作为增强细胞免疫的治疗剂的用途
Murad et al. CPG-7909 (PF-3512676, ProMune®): Toll-like receptor-9 agonist in cancer therapy
JP5745577B2 (ja) Cd40アゴニスト抗体/i型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
JP2009511452A5 (https=)
US20140056943A1 (en) Immuno-stimulant combination for prophylaxis and treatment of hepatitis c
Osada et al. Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects
Kang et al. The adjuvant effect of levamisole on killed viral vaccines
Yang et al. Role of toll‐like receptors in the pathogenesis of COVID‐19: Current and future perspectives
RU2639504C2 (ru) Химерные антигены для вакцины против вируса гепатита с
Mansilla et al. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein
Garcia et al. An overview of hepatitis C vaccines
Stone et al. Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly (I: C) and CD40 ligand plasmid DNA
EP2030628B1 (en) A peptide for preventing or treating liver damage and its derivant and the use
Weinberg The role of OX40 (CD134) in T-cell memory generation
Poordad et al. Developments in hepatitis C therapy during 2000–2002
WO2011063133A1 (en) LOW ANTIGEN-DOSE IMMUNIZATION FOR MAXIMIZING T-HELPER CELL 1 (T h1) IMMUNITY AGAINST DISEASE
CN1809584B (zh) 含有阳离子微粒和hcv e1e2 dna的组合物及其使用方法
EP3134118A1 (en) Particulate vaccine formulations for inducing innate and adaptive immunity
EP2992898A1 (en) T-cell adjuvant and its use for therapeutic or prophylactic vaccination
Mishra et al. Immunotherapy in liver diseases: a balance between immunity and tolerance
KR20040028924A (ko) Dna와 항원의 조합에 의해 효능이 증강된 백신포뮬레이션
Arcuri et al. Synergistic effect of gene‐electro transfer and adjuvant cytokines in increasing the potency of hepatitis C virus genetic vaccination
Immunotherapy Divergent Roles for CD4
Kurche et al. Type I Interferon-dependent T cell activation is mediated by IFN-dependent DC OX40L expression and independent of T cell IFNR expression